The U.S. Food and Drug Administration approved Dawnzera, Ionis Pharmaceuticals' medication for hereditary angioedema, marking the third new drug approved this year for the rare genetic condition. This is Ionis’ second wholly owned drug to market, underscoring the company's growing pipeline strength in rare diseases. The approval adds an important therapeutic option for patients suffering from recurrent angioedema attacks, a potentially life-threatening disorder characterized by swelling in various tissues.